Research

Research Goal:

The Bioprocess Systems Engineering Laboratory (BSEL) aims to advance precision biomanufacturing for cellular therapeutics by adopting a metabolomics-driven approach. This involves developing a deep understanding of cellular heterogeneity in advanced cell therapies (ACT), refining biomanufacturing processes, and enhancing the quality and effectiveness of ACT products.

Research Methods:

1. Metabolomics Database Development (WP1):

Create a detailed metabolomics database that captures the variability in cellular metabolism. The database will combine AI-driven analysis and experimental data collection, offering an accessible platform for real-time bioprocess evaluation.

2. Characterization of Cellular Heterogeneity (WP2):

Investigate cellular heterogeneity in ACT by analysing metabolic profiles. This research will assess how metabolic variations affect therapeutic outcomes and develop strategies to reduce these differences.

3. Precision Culture Media and Bioprocess Design (WP3):

Design metabolism-sensitive culture media and feeding strategies, using model-based approaches, to match the specific metabolic needs of different cell types.

This will optimize cell expansion and differentiation platforms for consistent, high-quality ACT production.

4. Identification of Metabolic Biomarkers (WP4):

Discover and validate critical metabolic biomarkers to monitor and control the biomanufacturing process, ensuring consistent and safe ACT products.

5. Implementation of Metabolism-Sensitive Biomanufacturing Techniques (WP5):

Leverage insights from the previous work packages to develop advanced biomanufacturing techniques that respond to cellular metabolism, leading to more reliable and reproducible ACT production.

Potential Outcomes:

  • Establishment of the first bioprocess-oriented database to address factors influencing ACT product quality and variability.

  • Improved control of cellular heterogeneity through metabolomics, leading to enhanced manufacturing strategies.

  • Development of precision culture media that ensures high-quality clinical product consistency.

  • Reduction in ACT production costs through optimized cell sourcing and treatment strategies.

  • Enhanced delivery of safe, effective, and personalized cellular therapeutics.

Cell Types